We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tesaro, Clovis Rally on FDA Priority Review for Lynparza sNDA
Read MoreHide Full Article
Shares of TESARO, Inc. and Clovis Oncology were up on Tuesday, after AstraZeneca plc (AZN - Free Report) and partner Merck (MRK - Free Report) announced that the FDA has granted priority review to their regulatory application looking for label expansion of its PARP inhibitor, Lynparza, in the first-line setting for advanced ovarian cancer.
Notably, TESARO and Clovis market PARP inhibitors, Zejula and Rubraca, respectively. Both these companies are also developing the respective drugs, Zejula and Rubraca, as a first-line maintenance treatment for advanced ovarian cancer.
While TESARO gained 8.4%, Clovis was up 5.4% on Nov 13. However, so far this year, shares of TESARO and Clovis’ have lost 64.7% and 77.6%, respectively, compared with the biotech industry’s 19.4% decline.
The supplemental new drug application (sNDA) is looking for approval of Lynparza, as maintenance treatment in newly-diagnosed advanced ovarian cancer patients with BRCA mutation who have achieved complete or partial response, following first-line standard platinum-based chemotherapy. A decision from FDA is expected in the first quarter of 2019.
In fact, Lynparza’s sNDA is the first regulatory application in the PARP inhibitor segment seeking label expansion in first-line maintenance setting.
The three approved PARP inhibitors at present compete in the second-line maintenance setting for ovarian cancer, irrespective of BRCA mutation and third or later line setting in BRCA-mutated ovarian cancer.
Successful development of these drugs in first-line setting is likely to improve sales for each. This is because first-line setting represents the largest addressable ovarian cancer patient population and only three drugs compete in the PARP inhibitor segment. Moreover, data from AstraZeneca’s phase III SOLO-1 study, which evaluated Lynparza in ovarian cancer as first-line maintenance, showed that duration of progression free survival in first-line is significantly higher than in recurrence setting. This suggest better acceptance of PARP inhibitors in first-line setting.
Meanwhile, on their third quarter earnings call, TESARO has stated that market share of PARP inhibitors’ in the ovarian cancer market has stagnated. Thus, label expansion in first-line setting might be a way to boost market share in the highly crowded advanced ovarian cancer market.
A phase III study — PRIMA — is evaluating Zejula monotherapy for treating advanced ovarian cancer in first-line maintenance setting. In the second quarter, TESARO has completed enrolment in the study and the top-line data is expected in 2019. A phase III study, ATHENA, is currently enrolling patients and evaluating Rubraca in combination with Bristol-Myers’ Opdivo in similar indication. Both these studies evaluate the therapies in ovarian cancer irrespective of BRCA mutation, which represents a larger patient population than BRCA-mutant ovarian cancer patients in Lynparza’s SOLO-1 study.
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
Image: Bigstock
Tesaro, Clovis Rally on FDA Priority Review for Lynparza sNDA
Shares of TESARO, Inc. and Clovis Oncology were up on Tuesday, after AstraZeneca plc (AZN - Free Report) and partner Merck (MRK - Free Report) announced that the FDA has granted priority review to their regulatory application looking for label expansion of its PARP inhibitor, Lynparza, in the first-line setting for advanced ovarian cancer.
Notably, TESARO and Clovis market PARP inhibitors, Zejula and Rubraca, respectively. Both these companies are also developing the respective drugs, Zejula and Rubraca, as a first-line maintenance treatment for advanced ovarian cancer.
While TESARO gained 8.4%, Clovis was up 5.4% on Nov 13. However, so far this year, shares of TESARO and Clovis’ have lost 64.7% and 77.6%, respectively, compared with the biotech industry’s 19.4% decline.
The supplemental new drug application (sNDA) is looking for approval of Lynparza, as maintenance treatment in newly-diagnosed advanced ovarian cancer patients with BRCA mutation who have achieved complete or partial response, following first-line standard platinum-based chemotherapy. A decision from FDA is expected in the first quarter of 2019.
In fact, Lynparza’s sNDA is the first regulatory application in the PARP inhibitor segment seeking label expansion in first-line maintenance setting.
The three approved PARP inhibitors at present compete in the second-line maintenance setting for ovarian cancer, irrespective of BRCA mutation and third or later line setting in BRCA-mutated ovarian cancer.
Successful development of these drugs in first-line setting is likely to improve sales for each. This is because first-line setting represents the largest addressable ovarian cancer patient population and only three drugs compete in the PARP inhibitor segment. Moreover, data from AstraZeneca’s phase III SOLO-1 study, which evaluated Lynparza in ovarian cancer as first-line maintenance, showed that duration of progression free survival in first-line is significantly higher than in recurrence setting. This suggest better acceptance of PARP inhibitors in first-line setting.
Meanwhile, on their third quarter earnings call, TESARO has stated that market share of PARP inhibitors’ in the ovarian cancer market has stagnated. Thus, label expansion in first-line setting might be a way to boost market share in the highly crowded advanced ovarian cancer market.
A phase III study — PRIMA — is evaluating Zejula monotherapy for treating advanced ovarian cancer in first-line maintenance setting. In the second quarter, TESARO has completed enrolment in the study and the top-line data is expected in 2019. A phase III study, ATHENA, is currently enrolling patients and evaluating Rubraca in combination with Bristol-Myers’ Opdivo in similar indication. Both these studies evaluate the therapies in ovarian cancer irrespective of BRCA mutation, which represents a larger patient population than BRCA-mutant ovarian cancer patients in Lynparza’s SOLO-1 study.
AstraZeneca PLC Price
AstraZeneca PLC Price | AstraZeneca PLC Quote
Zacks Rank
AstraZeneca currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
See them today for free >>